Ontology highlight
ABSTRACT: Context
Klinefelter syndrome (KS) is a common condition in males, resulting in androgen deficiency and cardiometabolic diseases. These interrelated conditions may be present in prepubertal boys with KS.Objective
To determine whether supplemental low-dose androgen has a beneficial effect on body composition in prepubertal boys with KS.Design, setting, and participants
We conducted a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial in 93 boys with KS aged 4 to 12 years.Interventions
Oral oxandrolone (Ox) 0.06 mg/kg/d or placebo for 2 years.Outcome measures
The primary outcome was percent body fat standard deviation score (%BF SDS) at 2 years. Secondary outcomes included additional measures of cardiometabolic health and safety.Results
The %BF SDS at 2 years was significantly lower in the treatment (0.29 ± 0.76 SDS) compared with placebo group (0.81 ± 0.72 SDS) after adjusting for age and baseline %BF SDS (95% confidence interval for the difference between means -0.86 to -0.19 SDS, P = 0.009). Ox resulted in lower triglycerides (P = 0.043), but also lower high-density lipoprotein (HDL) cholesterol (P < 0.001) and a more rapid advancement in bone age (P = 0.011).Conclusions
Ox has positive effects on measures of cardiometabolic health in prepubertal boys with KS; however, it does lower HDL cholesterol and advance bone age.
SUBMITTER: Davis SM
PROVIDER: S-EPMC5413098 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature

The Journal of clinical endocrinology and metabolism 20170101 1
<h4>Context</h4>Klinefelter syndrome (KS) is a common condition in males, resulting in androgen deficiency and cardiometabolic diseases. These interrelated conditions may be present in prepubertal boys with KS.<h4>Objective</h4>To determine whether supplemental low-dose androgen has a beneficial effect on body composition in prepubertal boys with KS.<h4>Design, setting, and participants</h4>We conducted a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial in 93 b ...[more]